Brief exposure to hyperoxia is associated with reduced Plasmodium falciparum in vitro tolerance to Dihydroartemisinin

Clicks: 19
ID: 329653
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #445 of 506 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 506 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract The ring-stage survival assay (RSA) is a valuable tool for assessing in vitro Plasmodium falciparum tolerance to Dihydroartemisinin. However, laboratories with unreliable or no access to premixed commercial gas may not perform the RSA under the recommended physiological normoxia. We measured survival rates of ART-sensitive and ART-resistant strains in the normoxic commercial gas and hyperoxic candle jar gas. RSA read-outs for ART-resistant strains were significantly lower (p<0.05) under hyperoxia compared to physiological normoxia, whereas those of ART-sensitive strains were unaltered. These findings have important implications for interlaboratory comparison of RSA data and understanding the mechanisms of resistance to endoperoxide drugs.
Reference Key
openalex_W7214160715 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag490
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.